InstalabLoading...
InstalabLoading...
Some of the most dangerous diseases in medicine are the ones that quietly reshape your organs for years before you feel a thing. IgG4-related disease is one of them. It can thicken your pancreas, narrow your bile ducts, scar your kidneys, and swell your salivary glands, all while your routine blood work looks completely normal. The single most useful blood test for raising suspicion of this condition is serum IgG4 (immunoglobulin G4), a measurement of one specific antibody subtype that your immune system overproduces when this disease is active.
A high IgG4 does not confirm the diagnosis on its own, and a normal result does not rule it out. But when combined with symptoms, imaging, and sometimes a tissue biopsy, this number can dramatically shorten the time from confusion to clarity. If you have unexplained organ swelling, autoimmune pancreatitis, or an inflammatory mass that mimics cancer, knowing your IgG4 level is one of the first steps toward getting the right answer.
Your immune system produces several classes of antibodies, and the most abundant class, IgG (immunoglobulin G), comes in four subtypes numbered 1 through 4. IgG4 is normally the rarest, making up just 3 to 6 percent of your total IgG. It is produced by a type of white blood cell called a plasma cell, which is the final form of a B cell that has been activated and instructed to make antibodies.
IgG4 has an unusual property: it tends to dampen inflammation rather than amplify it. Unlike IgG1 and IgG3, it does not efficiently activate the complement system (a cascade of proteins that attacks foreign invaders) or recruit immune killer cells. For this reason, it was long considered a "tolerogenic" or calming antibody. That reputation is partly deserved in allergy, where rising IgG4 after immunotherapy signals your body is learning to tolerate an allergen. But in IgG4-related disease, the story is different: the antibody accumulates alongside dense scar tissue and organ damage, making it a marker of something far from benign.
IgG4-related disease (IgG4-RD) is a chronic condition in which your immune system drives inflammation and scarring (fibrosis) across multiple organs. The pancreas and bile ducts are the most commonly affected, but the condition can also involve the salivary and tear glands, kidneys, lungs, aorta, retroperitoneum (the tissue behind the abdominal organs), and thyroid. It predominantly affects middle-aged and older men, though women and younger adults can also develop it.
What makes IgG4-RD particularly tricky is that it often mimics cancer or other autoimmune diseases. A pancreatic mass that looks like pancreatic cancer on a scan may turn out to be IgG4-related pancreatitis. A kidney lesion that suggests a tumor may be IgG4-related kidney disease. In a cohort of 125 patients, elevated serum IgG4 correlated with more organs being involved and a more severe disease pattern overall. The condition responds well to treatment, especially early on, but delayed diagnosis allows irreversible fibrosis to set in.
In an analysis of 765 patients across two international cohorts, four distinct clinical patterns (phenotypes) of IgG4-RD were identified: one limited to the head and neck, one centered on the pancreas and bile ducts, one involving the retroperitoneum and aorta, and one affecting multiple organ systems simultaneously. Being Asian or female was associated with head and neck-limited disease, while the pancreatic and multi-organ patterns carried higher treatment demands.
Beyond its role in diagnosing IgG4-RD, serum IgG4 may carry information about cardiovascular risk. In a large substudy from the REAL-CAD trial (a Japanese study of over 12,000 patients with stable coronary artery disease), researchers measured baseline serum IgG4 and followed patients for a median of 3.9 years. Those in the highest quarter of IgG4 levels were about 44% more likely to experience a major cardiovascular event (heart attack, stroke, cardiovascular death, or unstable angina) compared to those in the lowest quarter. When coronary procedures were added to the outcome, the risk was about 60% higher.
These associations held after adjusting for age, sex, statin dose, high-sensitivity CRP (a measure of inflammation), BMI (body mass index), kidney function, blood pressure, diabetes, and cholesterol levels. This suggests that IgG4 reflects a layer of cardiovascular risk that standard markers do not fully capture. Case reports and a systematic review have also documented coronary artery involvement in IgG4-RD itself, with inflammation and fibrosis narrowing the coronary arteries and, in rare cases, causing sudden cardiac death.
A meta-analysis pooling 10 cohort studies found that people diagnosed with IgG4-RD had roughly 2.6 times the overall cancer rate compared to the general population. The risk was most striking for lymphoma, where the rate was extremely elevated, and for pancreatic cancer, where it was about 4 times higher. Lung and gastric cancer rates were not significantly increased.
This does not mean that a high serum IgG4 level causes cancer. The relationship likely runs in both directions: IgG4-RD may create a chronic inflammatory environment that promotes certain cancers, and some cancers (especially pancreatic and lymphoid malignancies) can themselves elevate IgG4, creating diagnostic confusion. If you have confirmed IgG4-RD, this data supports regular screening for malignancy as part of your follow-up.
Serum IgG4 is a useful but imperfect screening tool for IgG4-RD. At the commonly used cutoff of 135 mg/dL (1.35 g/L), a large U.S. cohort of 1,376 patients found sensitivity around 90% (it catches most true cases) but specificity around 60% (many people with high IgG4 do not have IgG4-RD). The positive predictive value was only 34%, meaning roughly two out of three elevated results are false positives. However, the negative predictive value was 96%, so a normal result substantially reduces the likelihood of IgG4-RD.
A 27-study meta-analysis of approximately 1,700 IgG4-RD cases and 18,000 controls reported pooled sensitivity of 86% and specificity of 90%. Diagnostic performance was somewhat better in Asian populations than in Caucasian populations, and using a higher cutoff of 280 mg/dL (2.8 g/L) pushed specificity above 96% but dropped sensitivity to about 35 to 57%.
| Cutoff | Sensitivity | Specificity | Best Use |
|---|---|---|---|
| 135 mg/dL (1.35 g/L) | About 86 to 90% | About 60 to 90% | Initial screening when suspicion exists |
| 280 mg/dL (2.8 g/L) | About 35 to 57% | About 91 to 96% | Stronger confirmation, fewer false positives |
What this means for you: a normal IgG4 is reassuring but does not completely exclude IgG4-RD. About half of biopsy-proven cases can have normal serum IgG4, particularly in patients with single-organ involvement. And an elevated IgG4 does not equal a diagnosis. Allergic diseases, other autoimmune conditions, infections, and even some cancers can raise IgG4 without IgG4-RD being present.
IgG4 assays are not well standardized across labs. Different manufacturers use different calibration materials, which means the same blood sample can produce meaningfully different IgG4 values depending on which assay your lab uses. This makes it especially important to compare your results within the same lab over time, rather than across different labs or assay platforms. The ranges below are drawn from published clinical studies and diagnostic criteria. They provide useful orientation, but your lab may report slightly different numbers.
| Range | What It Suggests |
|---|---|
| Below 135 mg/dL (1.35 g/L) | Within the normal reference range for most adults. IgG4-RD is less likely but not excluded. |
| 135 to 280 mg/dL (1.35 to 2.8 g/L) | Mildly to moderately elevated. Warrants clinical correlation with symptoms, imaging, and sometimes biopsy. |
| Above 280 mg/dL (2.8 g/L) | Strongly elevated. More specific for IgG4-RD when clinical features are present. Also associated with multi-organ involvement and higher relapse risk. |
Compare your results within the same lab over time for the most meaningful trend.
Several factors influence your baseline IgG4 level independently of disease. Men tend to have higher serum IgG4 than women. In a study of over 12,700 adults, IgG and IgG subclass concentrations differed significantly by sex and race, with Black individuals having higher total IgG levels than White individuals. A separate study of 413 healthy Spanish adults confirmed higher IgG4 in males and a tendency for levels to decrease with age.
A large Japanese health checkup study of 3,240 adults found that smoking was significantly and positively correlated with elevated serum IgG4 levels. If you smoke and have a mildly elevated IgG4, the smoking itself may be contributing to the number. Genetic factors also play a role: a genome-wide study of nearly 9,000 people identified variants at five gene locations that influence IgG subclass levels.
The biggest source of misleading IgG4 results is assay variability between labs. One study across four Swiss labs found that the same patient sample produced clinically different IgG4 values depending on the assay reagent used. This can push a result above or below a diagnostic cutoff without any real change in your biology. Always compare results from the same lab and the same assay platform.
A single IgG4 reading is a snapshot. Because your baseline is influenced by sex, age, genetics, smoking, and allergic status, a single elevated value tells you less than a trajectory. If you are being evaluated for possible IgG4-RD, an initial measurement establishes your baseline. If treatment begins (typically glucocorticoids or rituximab), serial measurements show whether IgG4 is falling in response, which is one sign that treatment is working.
In a prospective U.K. cohort of over 1,500 patients, persistently elevated IgG4 levels above 280 mg/dL after treatment were associated with higher rates of relapse. This means your trend over time carries prognostic weight: a level that drops briskly with treatment and stays down is a better sign than one that falls briefly and climbs again.
If you are tracking IgG4, get a baseline, retest 3 to 6 months after any intervention or clinical change, and then at least every 6 to 12 months during active monitoring. Always use the same lab and assay to make your numbers comparable.
If your IgG4 comes back elevated, the next step is not panic but context. Ask: do you have symptoms that could fit IgG4-RD? Unexplained swelling in the salivary or tear glands, abdominal pain suggestive of pancreatitis, jaundice without a clear cause, kidney function decline, or a mass that appeared on imaging? If yes, the elevated IgG4 adds weight to the suspicion and you should pursue imaging (CT or MRI of the affected organ) and, in many cases, a tissue biopsy with IgG4 immunostaining.
Companion tests that add context include total IgG (to assess the IgG4-to-total-IgG ratio), total IgE and eosinophil count (both frequently elevated in IgG4-RD and useful for predicting relapse), and complement levels (C3 and C4, which when low suggest kidney or multi-organ involvement). If multiple organs appear affected, formal classification using the 2019 ACR/EULAR (American College of Rheumatology/European League Against Rheumatism) criteria provides a structured scoring system that weighs clinical, lab, imaging, and pathology findings together.
If your IgG4 is normal but you have strong clinical suspicion, do not dismiss the diagnosis. Up to half of biopsy-confirmed IgG4-RD cases have normal serum IgG4, particularly when only a single organ is involved. In that scenario, tissue biopsy remains the gold standard. A rheumatologist, gastroenterologist, or specialist experienced with IgG4-RD is the right person to guide the workup.
Evidence-backed interventions that affect your IgG4 level
IgG4 is best interpreted alongside these tests.